Linagliptin

CAS no.: 668270-12-0

Type: API

Usage: Diabetes

Technical description
Linagliptin is a xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. It has a role as a hypoglycemic agent and an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor. It is a member of quinazolines and an aminopiperidine. It is functionally related to a 7H-xanthine.

IUPAC name: 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione.

Molecular formula: C₂₅H₂₈N₈O₂

Molecular Weight: 472.5 g/mol

Class: It is an oral antidiabetic medication belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, also known as “gliptins”.

Synonyms: BI-1356, BI 1356, BI-1356-BS, BI1356.